Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

BACKGROUND: Tumour necrosis factor α (TNFα) is a proinflammatory cytokine involved in the pathogenesis of rheumatoid arthritis (RA). Treatment with TNFα inhibitors reduces disease activity and improves outcomes for patients with RA. This study evaluated the efficacy and safety of certolizumab pegol...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, R, Vencovsky, J, van Vollenhoven, R F, Borenstein, D, Box, J, Coteur, G, Goel, N, Brezinschek, H-P, Innes, A, Strand, V
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674555/
https://www.ncbi.nlm.nih.gov/pubmed/19015206
http://dx.doi.org/10.1136/ard.2008.099291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674555/
https://www.ncbi.nlm.nih.gov/pubmed/19015206
http://dx.doi.org/10.1136/ard.2008.099291

Ejemplares similares